Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Geburtshilfe und Frauenheilkunde·2026

Same author

ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026

Same author

Cervical Cancer Complexity: Exploring the Coexistence of CIN3 and Glandular Lesions.

Infectious disorders drug targets·2026

Same author

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

NPJ breast cancer·2026

Same author

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.

Gynecologic oncology·2025

Search research articles

Related Experiment Video

Updated: Dec 29, 2025

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Low-grade Serous Tumors: Are We Making Progress?

Nina Pauly¹, Sarah Ehmann¹, Enzo Ricciardi¹

¹Gynaecology and Gynaecological Oncology, Kliniken Essen-Mitte, Henricistraße 92, 45136, Essen, Germany.

Current Oncology Reports

|January 29, 2020

Summary

This summary is machine-generated.

Novel MEK inhibitors show promise for low-grade serous ovarian cancer (LGSOC). These targeted treatments, including trametinib, offer potential alternatives to standard therapies and should be considered for clinical practice.

Keywords:

Low-grade serous - rare tumor MEK inhibitor Ovarian cancer

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Dec 29, 2025

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Area of Science:

Gynecologic Oncology
Medical Oncology
Translational Cancer Research

Background:

Low-grade serous ovarian cancer (LGSOC) is a distinct subtype requiring specific treatment strategies.
Current management relies on surgery and conventional therapies, with limited options for advanced or recurrent disease.

Purpose of the Study:

To review the current clinical standards for LGSOC management.
To elaborate on surgical and standard treatment evidence.
To discuss recent findings and novel therapeutic approaches for LGSOC.

Main Methods:

Literature review of clinical trials and studies on LGSOC treatments.
Analysis of data from recent multicenter trials investigating MEK inhibitors.
Evaluation of evidence for surgery, hormonal therapy, bevacizumab, and chemotherapy.

Main Results:

Two large trials presented MEK inhibitors (binimetinib and trametinib) in LGSOC.
Binimetinib showed activity, particularly in KRAS-mutated LGSOC.
Trametinib improved progression-free survival in relapsed LGSOC, suggesting it as a viable targeted treatment.

Conclusions:

MEK inhibitors represent a promising alternative treatment for LGSOC.
Surgery remains a critical component of LGSOC management.
Combination therapies including hormonal therapy, bevacizumab, and targeted agents like trametinib warrant integration into clinical practice.